Purpose {#sec1}
=======

Endometrial cancer is a common gynecological cancer, with approximately 61,000 new cases estimated in 2016. The gold standard for managing the disease is surgery, consisting of a total abdominal hysterectomy and bilateral salpingo-oophorectomy, with or without lymph node sampling or dissection \[[@cit0001],[@cit0002],[@cit0003],[@cit0004]\]. The use of adjuvant therapy such as external beam radiotherapy (EBRT) and/or vaginal brachytherapy (VBT) is based on disease stage and risk factors for recurrence, and can be individualized.

Historically, low-dose-rate (LDR) brachytherapy has been used to treat endometrial cancer \[[@cit0005]\]. In the 1970s, high-dose-rate (HDR) brachytherapy was developed to overcome some of the potential disadvantages of LDR brachytherapy such as radiation exposure to the professional staff, need for hospitalization, risk of thromboembolism due to bed immobilization, and patient discomfort.

One potential late side effect of brachytherapy is vaginal stenosis, which occurs from irreversible mucosal damage from radiation. Severe stenosis may lead to the inability to perform an adequate pelvic examination and to sexual dysfunction, and can negatively affect the patient's quality of life \[[@cit0006],[@cit0007]\].

Few studies compare LDR and HDR VBT in the treatment of endometrial cancer, especially in terms of late toxicity. We retrospectively analyzed our institutional results for endometrial cancer patients treated with either HDR or LDR VBT after EBRT in terms of survival and safety.

Material and methods {#sec2}
====================

Patient selection {#sec2.1}
-----------------

Patients diagnosed with endometrial cancer who underwent EBRT and VBT from January 2000 to December 2014 were retrospectively considered for this study. All data were selected from the intranet hospital multidivisional electronic database, Spider's Net \[[@cit0008]\] in the frame of the COBRA system \[[@cit0009]\]. Inclusion criteria were histologically proven diagnosis of endometrial cancer, EBRT \> 40 Gy, VBT boost, and follow-up \> 6 months. In all cases, the indication for the treatment was discussed in a multidisciplinary gynecologic tumor board. All patients provided informed consent.

Patient treatment {#sec2.2}
-----------------

All patients were treated at our institution with total hysterectomy and bilateral salpingo-oophorectomy, with or without lymph node dissection. All patients received EBRT to the pelvic lymph nodes at a dose of 45 Gy, 1.8 Gy/day, for 5 days/week, performed with a 3-dimensional technique. A sub-sequential VBT boost was administered in all patients in one fraction. Depending on the institutional protocol in use at the time of therapy, one of two modalities were used: VBT boost in LDR, with a total dose of 25 Gy, or VBT boost in HDR, with a dose of 7 Gy in one fraction prescribed at 0.5 cm from the surface of the applicator. The proximal half to two-thirds (based on clinical presentation) of the vagina was irradiated. Vaginal cylinders ranged from 2.0-3.5 cm.

External beam radiotherapy technique {#sec2.3}
------------------------------------

For EBRT, simulation and treatment were performed with the patient in a prone position using an up-down table device \[[@cit0010]\] aimed to reduce the small bowel volume in the treatment field. A computed tomography (CT) scan was used for EBRT planning in all patients. The pelvic volume (clinical target volume \[CTV\] 2) was defined as the upper two-thirds of the vagina (if not involved) or the whole vagina (if involved at pathologic evaluation), obturator lymph nodes, external iliac nodes, internal iliac nodes, and presacral nodes. Because of organ motion and setup uncertainties, a planning target volume (PTV) 2 was defined by adding an 8 mm isotropic margin to the CTV.

Brachytherapy technique {#sec2.4}
-----------------------

Before 2012, patients who received brachytherapy were treated using the LDR system, which delivers a high-dose of radiation at a low-dose-rate from an applicator placed temporary in the organ. The patients had bowel preparation and were on a constipating regimen, and prophylactic measures were taken for thromboembolic risk.

After disinfecting the external genitalia and positioning the urinary catheter and rectal probe, vaginal applicator of varying circumferences was inserted without anesthesia or under local anesthetic.

Antero-posterior and lateral radiographs or CT-simulation after 2010 were performed to identify the target and organs at risk (bladder and rectum). The LDR VBT dose was 25 Gy, which was prescribed at 0.5 cm from the surface of the applicator. The proximal half to two-thirds of the vagina was irradiated. Vaginal cylinders ranged from 2.0-3.5 cm. The treatment plan was performed using PLATO, or OncentraBrachy after 2010 with a 3-dimensional technique. The treatment was performed by the Selectron device with ^137^Cs before 2010, and with the MicroSelectron device with an HDR ^192^Ir source after 2010.

For HDR treatments from 2012, the same preparation as for LDR treatment was required and a similar vaginal applicator insertion was performed. The patient was simulated using a CT scan and the treatment plan was performed on the OncentraBrachy treatment planning system (TPS) with a 3-dimensional technique. The HDR VBT dose prescribed was 7 Gy in one fraction at 5 mm from the applicator surface by a MicroSelectron device with an ^192^Ir source. The proximal half to two-thirds of the vagina was irradiated. Vaginal cylinders ranged from 2.0-3.5 cm.

Patient follow-up {#sec2.5}
-----------------

After therapy, all patients were periodically evaluated every 3 months during the first year, every 4 months during the second year, every 6 months until 5 years, and annually after 5 years. According to an internal QA protocol, gastrointestinal and genitourinary adverse events were evaluated according to the RTOG (Radiation Therapy Oncology Group) morbidity grading system scale ([Table 1](#t0001){ref-type="table"}) \[[@cit0011]\], based on information reported in the clinical chart, while vaginal mucosal toxicity was defined according to the CTCAE version 4.0. It was assessed from the symptoms reported by the patient, and any mucosal changes noted on speculum and bimanual exams at each visit.

###### 

RTOG late radiation morbidity scoring schema

  Organ/tissue            Grade 0   Grade 1                                                                                           Grade 2                                                                                                         Grade 3                                                                                                                                                 Grade 4
  ----------------------- --------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Small/large intestine   None      Mild diarrhea; mild cramping; bowel movement 5 times daily; slight rectal discharge or bleeding   Moderate diarrhea and colic; bowel movement \> 5 times daily; excessive rectal mucus or intermittent bleeding   Obstruction or bleeding, requiring surgery                                                                                                              Necrosis/perforation fistula
  Bladder                 None      Slight epithelial atrophy; minor telangiectasia (microscopic hematuria)                           Moderate frequency; generalized telangiectasia; intermittent macroscopic hematuria                              Severe frequency and dysuria; severe generalized telangiectasia (often with petechiae); frequent hematuria; reduction in bladder capacity (\< 150 cc)   Necrosis/contracted bladder (capacity \< 100 cc); severe hemorrhagic cystitis

Statistical analyses {#sec2.6}
--------------------

Statistical analysis was performed using MedCalc software ([www.medcalc.be](http://www.medcalc.be)). Overall survival (OS) was calculated using the Kaplan-Meier method. Univariate and multivariate logistic regressions (*T*-test) for toxicity analyses were performed.

Results {#sec3}
=======

We analyzed a total of 200 patients treated with EBRT, which was combined with HDR VBT boost in 78 patients and LDR VBT boost in 122 patients. Patient characteristics are summarized in [Table 2](#t0002){ref-type="table"}.

###### 

Patient characteristics

  Patient characteristics           Total         HDR          LDR
  --------------------------------- ------------- ------------ ------------
  Age (median)                      63 (31-88)    64 (36-88)   62 (47-88)
  Histology                                                    
   Adenocarcinoma                   200 (100%)    78 (39%)     122 (61%)
  Stage                                                        
   IA                               14 (7%)       12 (85%)     2 (15%)
   IB                               55 (28%)      39 (70%)     16 (30%)
   IC                               59 (29%)      2 (3%)       57 (97%)
   II                               44 (22%)      10 (22%)     34 (78%)
   IIIA                             13 (6.5%)     5 (38%)      8 (62%)
   IIIB                             3 (1.5%)      2 (66%)      1 (34%)
   IIIC                             12 (6%)       8 (66%)      4 (34%)
  Grading                                                      
   Well differentiated              25 (12.5%)    4 (16%)      16 (84%)
   Moderately well-differentiated   97 (48.5%)    32 (33%)     66 (67%)
   Poorly differentiated            78 (39%)      42 (54%)     40 (46%)
  Miometrial invasion                                          
   \< 50%                           55 (27.5%)    24 (44%)     30 (66%)
   \> 50%                           145 (72.5%)   54 (37%)     92 (63%)

LDR -- low-dose-rate, HDR -- high-dose-rate

With a median follow-up of 25 months (range, 6-163 months), the 5-year OS was 98% vs. 97% in the LDR and HDR group, respectively (*p* = 0.37) ([Figure 1](#f0001){ref-type="fig"}). The 5-year local control rate (LC) was 93% in both groups (*p* = 0.81) ([Figure 2](#f0002){ref-type="fig"}). In multivariate analyses, none of the investigated factors (age, stage, grading, treatment) showed an impact on OS (*p* = 0.37) and LC (*p* = 0.81).

![Overall survival](JCB-10-33588-g001){#f0001}

![Local control](JCB-10-33588-g002){#f0002}

Toxicity {#sec3.1}
--------

The treatment was generally well tolerated. The normal tissues at risk for developing acute radiation-related complications after treatment for endometrial cancer are in the genitourinary or gastrointestinal tracts. Grade 3 acute gastrointestinal toxicity (proctitis or diarrhea) were observed in 3 patients in the LDR group and 1 patient in the HDR group (*p* = 0.0014). Genitourinary acute toxicity (severe frequency and dysuria) was greater in the LDR group compared with the HDR group (*p* = 0.0195) ([Figure 3](#f0003){ref-type="fig"}).

![Acute treatment complications correlated with treatment](JCB-10-33588-g003){#f0003}

Regarding vaginal stenosis (reported at least six months from the date of brachytherapy), no significant difference was observed between the two groups (*p* = 0.67); even if comparing the grade 0-2 vs. grade 3 toxicities between groups, we observed a significant difference (*p* = 0.004) ([Figure 4](#f0004){ref-type="fig"}). However, in some patient files, a stenosis was noted but not specified according to the grading scale. Therefore, these data are not available for all patients (16 patients of HDR group and 9 patients for LDR group).

![Vaginal stenosis correlated with treatment](JCB-10-33588-g004){#f0004}

Discussion {#sec4}
==========

VBT plays an important role in adjuvant treatment of endometrial cancer. The PORTEC 2 trial \[[@cit0012]\] showed the efficacy of post-operative VBT in improving local control after abdominal hysterectomy/bilateral salpingo-oophorectomy compared with pelvic EBRT. One significant late toxicity described with this treatment is vaginal stenosis. It is due to the combination of adhesions and circumferential fibrosis in the upper vaginal tissue, with consequent narrowing and shortening of the vaginal vault. It can interfere with physical examinations and sexual functioning, and impact patients' quality of life.

In the PORTEC 2 trial, the rate of grade 2 vaginal mucosal atrophy was significantly higher after VBT than after EBRT; in the same study, grade 3 atrophy was reported in \< 1% of the patients receiving EBRT and 2% of those receiving VBT, despite similar sexual activity rates. However, specific rates of vaginal stenosis were not reported. Also, in the recently published study on the long-term health-related quality of life from the PORTEC-2 trial reported by de Bouer \[[@cit0013]\], vaginal stenosis was not considered.

Furthermore, in the literature, there are only a few studies comparing HDR and LDR VBT in the treatment of endometrial cancer. Bekerus *et al*. \[[@cit0014]\] published a study with similar survival results for the LDR and HDR groups but higher rates of late complications in the LDR group. In the same year, Rauthe *et al*. \[[@cit0015]\] showed that HDR after-loading irradiation improved the survival rate, with more frequent fistula formation in the HDR group, which was mainly produced by the low number of fractions and high single doses. In another retrospective study performed by Fayed *et al*. \[[@cit0016]\], intravaginal HDR VBT treatment results were compared to LDR VBT results, and no differences in survival and toxicity outcomes were observed. Neither of these studies reported on vaginal stenosis.

The observations from our study suggest that 5-year overall survival and 5-year local control were similar in the two groups. Subgroup analysis stratified by age, stage, grade, and treatment did not show statistically significant differences in terms of OS and LC. The occurrence of a higher rate of acute gastrointestinal toxicities in the LDR VBT group was probably caused by the development of the radiation technique over the years of this study. Regarding the technique used for brachytherapy, a 3-dimensional modality was introduced in 2010. No differences in vaginal stenosis rates were found between the two different VBT groups.

Limitations of this study are the same as those of any retrospective single-institutional analysis. Diagnostic imaging, surgical technique, and radiotherapy technique have changed over the years. However, the main limitation of this study is that we compared two different schedules of adjuvant treatments with different total doses in terms of EQD2: 7 Gy in HDR brachytherapy is equivalent to 9.92 Gy EQD~2~ with an a/b of 10 and 14 Gy EQD~2~ with an a/b of 3, while 25 Gy in LDR are equivalent to 25 Gy with a/b of 3. The HDR schedule was as suggested by ABS guidelines, while the LDR schedule was defined according to the institutional guidelines, and the delivered dose was probably higher than that of other studies reported in literature.

Another limitation of this retrospective study is that in some patient files the stenosis was described but not defined according the grading scale. These data are not available for all patients; for this reason, in the tables and graphs only the patients with available grade evaluation are reported.

The inter-observer uncertainty does not play a role in this analysis, since the same specialist recorded all toxicity data over the entire period of the present study.

Our interpretation of the data suggests less vaginal stenosis and acute gastrointestinal and genitourinary toxicity with HDR VBT than LDR VBT. However, it must be emphasized that the equivalent dose with HDR VBT was lower than that with LDR VBT. Probably there was a reduction in toxicity from using a lower overall dose. Nevertheless, this is still intriguing because lowering the dose did not result in a difference in local control.

Conclusions {#sec5}
===========

This retrospective study did not show differences in late toxicity outcomes and in local control values for patients receiving 25 Gy LDR or 7 Gy HDR VBT. With the introduction of HDR VBT, we observed a reduction in gastrointestinal and genitourinary toxicities without worsening of vaginal stenosis rates compared to LDR VBT-related data. In post-operative endometrial cancer, 7 Gy HDR VBT can be considered as safe, efficient, and complementary to 45 Gy conventional fractionated EBRT.
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